Keros Therapeutics, Inc. (“Keros”) (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it presented additional data from its two ongoing Phase 2 clinical trials of KER-050, one in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”) and one in patients with myelofibrosis (“MF”), at the 65th American Society of Hematology (“ASH”) Annual Meeting and Exposition, held in person in San Diego and virtually from December 9 through 12, 2023. In addition, Keros presented preclinical data showing that a research form of KER-050 promoted erythropoiesis in an animal model of MF, as well as preclinical data evaluating the treatment effect of activin receptor-like kinase 2 inhibition in a mouse model of iron-refractory iron deficiency anemia.
Related Posts
DA Davidson Upgrades Alamo Group to Buy, Raises Price Target to $196
DA Davidson analyst Michael Shlisky upgrades Alamo Group (NYSE:ALG) from Neutral to Buy and raises the price target from $173 to $196.
Baird Maintains Neutral on Allegion, Raises Price Target to $132
Baird analyst Timothy Wojs maintains Allegion (NYSE:ALLE) with a Neutral and raises the price target from $116 to $132.
Bankrupt Crypto Firm Three Arrows Capital’s Assets Frozen By New York Judge
Bankrupt crypto hedge fund Three Arrows Capital's (3AC) assets have been frozen by the New York bankruptcy court after a ruling from a federal judge on Tuesday.